LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Search

Charles River Laboratories International Inc

Закрыт

СекторЗдравоохранение

192.95 -0.65

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

191.68

Макс.

193.02

Ключевые показатели

By Trading Economics

Доход

2.9M

56M

Продажи

-27M

1B

P/E

Средняя по отрасли

592.3

77.671

Прибыль на акцию

2.43

Рентабельность продаж

5.529

Сотрудники

18,700

EBITDA

-23M

198M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

-0.27% downside

Рыночная статистика

By TradingEconomics

Рыночная капитализация

407M

9.2B

Предыдущая цена открытия

193.6

Предыдущая цена закрытия

192.95

Новостные настроения

By Acuity

50%

50%

158 / 374 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Strong Bullish Evidence

Charles River Laboratories International Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

14 дек. 2025 г., 22:53 UTC

Приобретения, слияния, поглощения

Fortescue to Take Full Control of US$101 Million Copper Miner Alta

13 дек. 2025 г., 00:04 UTC

Приобретения, слияния, поглощения

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

14 дек. 2025 г., 23:46 UTC

Обсуждения рынка

Gold Edges Higher Amid Some Tailwinds -- Market Talk

14 дек. 2025 г., 23:36 UTC

Обсуждения рынка

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

14 дек. 2025 г., 22:38 UTC

Приобретения, слияния, поглощения

Fortescue to Take Full Control of US$101M Copper Miner Alta

14 дек. 2025 г., 22:02 UTC

Приобретения, слияния, поглощения

Fortescue: Transaction Is Consistent With Critical Minerals Strategy

14 дек. 2025 г., 22:01 UTC

Приобретения, слияния, поглощения

Fortescue: Alta Owns the Canariaco Project in Northern Peru

14 дек. 2025 г., 22:01 UTC

Приобретения, слияния, поглощения

Fortescue: Alta Directors Unanimously Recommend Proposal, Will Vote in Favor

14 дек. 2025 г., 22:00 UTC

Приобретения, слияния, поглощения

Fortescue: Agreement Implies Total Equity Value of C$139 Million

14 дек. 2025 г., 22:00 UTC

Приобретения, слияния, поглощения

Fortescue to Pay C$1.40/Share for Securities It Does Not Already Own

14 дек. 2025 г., 21:59 UTC

Приобретения, слияния, поглощения

Fortescue to Acquire Remaining 64% of Alta Copper

14 дек. 2025 г., 17:00 UTC

Отчет

Tonka Trucks Gambled on Keeping Production in China and Survived -- Barely -- WSJ

14 дек. 2025 г., 08:30 UTC

Приобретения, слияния, поглощения

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

13 дек. 2025 г., 16:48 UTC

Приобретения, слияния, поглощения

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13 дек. 2025 г., 08:00 UTC

Приобретения, слияния, поглощения

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13 дек. 2025 г., 07:00 UTC

Приобретения, слияния, поглощения

A Chubb/AIG Deal Could Be Good for Shareholders and a Coup for Greenberg Family -- Barrons.com

13 дек. 2025 г., 00:24 UTC

Приобретения, слияния, поглощения

Want a Piece Of SpaceX? -- Barrons.com

12 дек. 2025 г., 23:49 UTC

Приобретения, слияния, поглощения

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12 дек. 2025 г., 22:52 UTC

Обсуждения рынка

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12 дек. 2025 г., 22:32 UTC

Отчет

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12 дек. 2025 г., 21:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

12 дек. 2025 г., 20:45 UTC

Отчет

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12 дек. 2025 г., 20:41 UTC

Обсуждения рынка

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12 дек. 2025 г., 20:20 UTC

Обсуждения рынка

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12 дек. 2025 г., 19:23 UTC

Отчет

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12 дек. 2025 г., 18:35 UTC

Приобретения, слияния, поглощения

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12 дек. 2025 г., 18:33 UTC

Приобретения, слияния, поглощения

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12 дек. 2025 г., 18:31 UTC

Обсуждения рынка

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12 дек. 2025 г., 17:49 UTC

Отчет

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12 дек. 2025 г., 17:34 UTC

Приобретения, слияния, поглощения

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

Сравнение c конкурентами

Изменение цены

Charles River Laboratories International Inc Прогноз

Целевая цена

By TipRanks

-0.27% падение

Прогноз на 12 месяцев

Средняя 192.5 USD  -0.27%

Максимум 225 USD

Минимум 165 USD

Основано на мнении 11 аналитиков Wall Street, спрогнозировавших целевые цены для Charles River Laboratories International Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

11 ratings

6

Покупка

5

Удержание

0

Продажа

Техническая оценка

By Trading Central

117.16 / 144.77Поддержка и Сопротивление

Краткосрочная

Strong Bullish Evidence

Среднесрочная

Weak Bullish Evidence

Долгосрочная

Bearish Evidence

Настроения

By Acuity

158 / 374Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat